Diverse technologies have a surprising number of common threads, whether in the technologies themselves or in the clinical applications. For this reason, manufacturers need to consider that: 1. A technology platform can be the launchpad for products in clinically diverse areas. Case in point, cell therapy, which as a fundamental scientific discipline can have uses [...]
Approximately 70 million surgical and procedure-based wounds are created each year in surgeries worldwide that offer potential for adjunctive products for surgical closure and securement. Some 23 million of these wounds are created during surgical procedures in the United States. Although it is possible that healing of all these wounds would be improved through use [...]
The worldwide market for products used in securement (sutures, staple, hemostasis, tapes, surgical sealants, high-strength glues) is characterized by both well established markets (sutures, staples and tapes) and novel products (surgical sealants, hemostasis and high-strength glues). The attractiveness of the surgical securement market is that there are some sizable segments that continue to demonstrate high [...]
Sutures and staples are at an aging stage in their product life cycle; there are numerous predicate devices, and the materials are well established and cover most of the spectrum of clinical need for suturing. However, a great number of procedure-enhancing devices have been developed in the last seven years, particularly as minimally invasive surgery [...]
The MedMarket Diligence Report #S175, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Market, 2009-2013," details the complete range of sealants & glues technologies used in traumatic, surgical and other wound closure, from tapes, sutures and staples to hemostats, fibrin sealants/glues and medical adhesives. The report details current clinical and technology developments in this huge and rapidly growing [...]
A truly striking amount of industry activity spanning company formation, industry consolidation, product developments and market introductions have taken place over the past two years in the markets for sealants, glues, hemostasis, wound closure and anti-adhesion. With a relatively low barrier to entry for products with well established routes to FDA and CE Mark approval, [...]
Haemacure Corporation last month disclosed the apparent clinical utility of its fibrin sealant in the prevention of post-surgical adhesion: Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, disclosed today the positive results of a second preclinical study conducted on the use of its proprietary lead [...]
Contact:
